Drugs / MK-8748
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06664502 | Nov 2024 → Mar 2026 overdue | diabetic macular edema, occlusion of tributary of retinal vein, wet macular degeneration | EyeBiotech Ltd. | Active not recruiting | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT07496567 | Apr 2026 → Jul 2028 expected | choroidal neovascularization, wet macular degeneration | EyeBiotech Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07440225 | Mar 2026 → Jun 2028 expected | choroidal neovascularization, wet macular degeneration | EyeBiotech Ltd. | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07705607 | Sep 2026 → Nov 2028 expected | diabetic macular edema | Merck Sharp & Dohme LLC | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07705555 | Aug 2026 → Oct 2028 expected | diabetic retinopathy, macular retinal edema | Merck Sharp & Dohme LLC | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-8748 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07705555 ↗ |
| Known as | EYE201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06664502 ↗ |
| Known as | Tiespectus | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07440225 ↗ |
| Route | Intravitreal | “intravitreal administration” NCT06664502 ↗ |